Big Tobacco’s Natural Move into the Cannabis Sector, Altria Group on Deck

Big Tobacco’s Natural Move into the Cannabis Sector, Altria Group on Deck

Wholly owned subsidiaries of Altria Group, Inc. (NYSE: MO) include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Nu Mark LLC (Nu Mark), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).

In the recent past, Altria’s has shown increasing interest in the cannabis sector. In fact, Tobacco sales haven’t improved much in the past few years, and therefore cannabis has become a natural extension for the tobacco industry. In fact, both the alcohol and tobacco industries are considering cannabis as a promising catalyst which could offset the weaker sales, price competition in cigarettes and alcohol beverages.

Furthermore, this could also be seen as Altria, hedging/diversifying its portfolio against the transition of consumer interest/preferences to cannabis products. In other words, the company is expanding along with buying insurance for its market risk profile.

Moreover, these investments positions Altria to participate in the emerging global cannabis sector, which it believes is poised for rapid growth over the next decade. Furthermore, it also creates a new growth opportunity in an adjacent category that is complementary to Altria’s core tobacco businesses.

Recent announcements:

Altria Makes $12.8 Billion Minority Investment in JUUL to Accelerate Harm Reduction and Drive Growth:

On 20th December Altria and JUUL sign service agreements to accelerate JUUL’s success switching adult smokers; JUUL has the unique opportunity to reach adult smokers through prime retail shelf space, inserts in cigarette packs and adult smoker database. JUUL will remain fully independent post this investment.

Strategic Rationale

Provides significant stake in the largest and fastest growing e-vapor company with a highly-talented management team, successful in-market products, and a strong innovation pipeline.

JUUL will remain independent and retain complete operational autonomy to capitalize on its entrepreneurial success.

Provides exposure to strong revenue and volume growth opportunity with attractive unit economics.

Investment in the leading U.S. e-vapor company complements Altria’s non-combustible product portfolio.

Exposure to significant international growth plans and global e-vapor profit pool.

Better positions Altria with adult smokers interested in alternatives while continuing to compete vigorously in all other tobacco product markets.

Altria to Make Growth Investment in Cronos Group

On December 7, 2018, the company announced that it has entered into an agreement to acquire newly issued shares in Cronos Group Inc. (Cronos Group) (TSX: CRON and NASDAQ: CRON), a leading global cannabinoid company, headquartered in Toronto, Canada. The transaction represents a 45% equity stake in Cronos Group, at a price of CAD $16.25 per share, for an aggregate investment by Altria of approximately USD $1.8 billion (approximately CAD $2.4 billion).

Management commentary:

“Investing in Cronos Group as our exclusive partner in the emerging global cannabis category represents an exciting new growth opportunity for Altria,” said Howard Willard, Altria’s Chairman, and Chief Executive Officer. “We believe that Cronos Group’s excellent management team has built capabilities necessary to compete globally, and we look forward to helping Cronos Group realize its significant growth potential.”

Expected synergies/value unlocking:

Robust financial flexibility: So far financials are concerned, “Altria delivered excellent third-quarter adjusted diluted earnings per share growth of 20% and continued to return large amounts of cash to its shareholders. Altria’ tobacco businesses are successfully executing against their strategies while making strategic investments to drive long-term success,” said Howard Willard, Altria’s Chairman, and Chief Executive Officer. “The management believes its year-to-date performance positions the company well to deliver on its full-year plans.”

Furthermore, due to the lower price levels, the stock is offering a solid 7.1% dividend yield for the first time in nearly a decade. The company has raised its dividend 53 times in the last 49 years.

Upcoming Presentation: The company will host a live audio webcast on Thursday, January 31, 2019, at 9:00 a.m. Eastern Time to discuss its 2018 fourth-quarter and full-year business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day.

Analyst ratings and target price: Per, 14 Wall Street analysts have issued ratings and price targets for Altria Group in the last 12 months. Their average twelve-month price target is $65.1925, suggesting that the stock has a possible upside of 43.91%. The high price target for MO is $75.00, and the low-price target for MO is $55.00. There are currently two sell ratings, four hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of “Hold. 

About the Company: Altria’s wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Nu Mark LLC (Nu Mark), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).

The brand portfolios of Altria’s tobacco operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, VERVE®, MarkTen®, and Green Smoke®. Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle®, Columbia Crest®, 14 Hands® and Stag’s Leap Wine Cellars™, and it imports and markets Antinori®, Champagne Nicolas Feuillatte™, Torres®, and Villa Maria Estate™products in the United States.

Q1 2019 Financial and Operational Highlights 

  • Net revenues increased 1.6% to $6.8 billion, primarily due to higher net revenues in the smokeable and smokeless products segments. Revenues net of excise taxes increased 3.3% to approximately $5.3 billion.
  • Reported diluted EPS increased 6.2% to $1.03, primarily driven by lower income taxes and fewer shares outstanding, partially offset by the 2017 gain on the AB InBev/SABMiller business combination.
  • Adjusted diluted EPS increased 20% to $1.08, primarily driven by lower income taxes and fewer shares outstanding.


  • In August 2018, Altria’s Board of Directors (Board) increased the regular quarterly dividend by 14.3% to $0.80 per share. Altria’s current annualized dividend rate is $3.20 per share, representing an annualized dividend yield of 5.2% as of October 19, 2018.
  • Altria paid over $1.3 billion in dividends in the third quarter.
  • Altria expects to maintain a dividend payout ratio target of approximately 80% of adjusted diluted EPS. Future dividend payments remain subject to the discretion of the Board.

Outlook: Altria tightens its guidance for 2018 full-year adjusted diluted EPS to be in a range of $3.95 to $4.03, representing a growth rate of 16.5% to 19% from an adjusted diluted EPS base of $3.39 in 2017 as shown in Schedule 10. This guidance range excludes the special items for the first nine months of 2018 shown in Table 1. Altria’s 2018 guidance reflects investments in focus areas for long-term growth, including innovative product development and launches, regulatory science, brand equity, retail fixtures, and future retail concepts.Altria expects its 2018 full-year adjusted effective tax rate will be in a range of approximately 23% to 24%.

Key risk factors and potential stock drivers:

  • Company’s ability to maintain its liquidity and financial flexibility to fund its incremental capital requirements.
  • ACB’ ability to acquire and incubate other marijuana companies as the sector consolidates
  •  In this sector, the regulatory framework and science are rapidly changing and evolving. Therefore, new companies are emerging, and regulatory risk always exists for the players in the industry. 
  • Unfavorable litigation outcomes could materially adversely affect the consolidated results of operations, cash flows or financial position of Altria or the businesses of one or more of its subsidiaries.
  • Significant federal, state and local governmental actions, including actions by the FDA, and various private sector actions may continue to have an adverse impact on the company’ tobacco subsidiaries’ businesses and sales volumes.

Stock Chart:

Altria Group (NYSE: MO) stock chart


  • On Tuesday, Jan 29th, 2019, MO is trading at $45.75, on volume of 7.3M shares exchanging hands. Market capitalization is $86.418 billion. The current RSI is 39.58
  • In the past 52 weeks, shares of MO have traded as low as $42.40 and as high as $70.66
  • At $45.75, shares of MO are trading below its 50-day moving average (MA) at $50.53 and its 200-day moving average (MA) at $55.70
  • The present support and resistance levels for the stock are at $43.39 & $46.45 respectively. 


Traders News Source Recent Reports

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.